TY - JOUR
T1 - Association of 3-methylglutaconic aciduria with sensori-neural deafness, encephalopathy, and Leigh-like syndrome (MEGDEL association) in four patients with a disorder of the oxidative phosphorylation
AU - Wortmann, S.
AU - Rodenburg, R. J.T.
AU - Huizing, M.
AU - Loupatty, F. J.
AU - de Koning, T.
AU - Kluijtmans, L. A.J.
AU - Engelke, U.
AU - Wevers, R.
AU - Smeitink, J. A.M.
AU - Morava, E.
PY - 2006/5
Y1 - 2006/5
N2 - In this paper, we describe a distinct clinical subtype of 3-methylglutaconic aciduria. 3-Methylglutaconic aciduria is a group of different metabolic disorders biochemically characterized by increased urinary excretion of 3-methylglutaconic acid. We performed biochemical and genetic investigations, including urine organic acid analysis, NMR spectroscopy, measurement of 3-methylglutaconyl-CoA hydratase activity, cardiolipin levels, OPA3 gene analysis and measurement of the oxidative phosphorylation in four female patients with 3-methylglutaconic aciduria. 3-Methylglutaconic aciduria type I, Barth syndrome, and Costeff syndrome were excluded as the activity of 3-methylglutaconyl-CoA hydratase, the cardiolipin levels, and molecular analysis of the OPA3 gene, respectively, showed no abnormalities. The children presented with characteristic association of hearing loss and the neuro-radiological evidence of Leigh disease. They also had neonatal hypotonia, recurrent lactic acidemia, episodes with hypoglycemia and severe recurrent infections, feeding difficulties, failure to thrive, developmental delay, and progressive spasticity with extrapyramidal symptoms. Our patients were further biochemically characterized by a mitochondrial dysfunction and persistent urinary excretion of 3-methylglutaconic acid.
AB - In this paper, we describe a distinct clinical subtype of 3-methylglutaconic aciduria. 3-Methylglutaconic aciduria is a group of different metabolic disorders biochemically characterized by increased urinary excretion of 3-methylglutaconic acid. We performed biochemical and genetic investigations, including urine organic acid analysis, NMR spectroscopy, measurement of 3-methylglutaconyl-CoA hydratase activity, cardiolipin levels, OPA3 gene analysis and measurement of the oxidative phosphorylation in four female patients with 3-methylglutaconic aciduria. 3-Methylglutaconic aciduria type I, Barth syndrome, and Costeff syndrome were excluded as the activity of 3-methylglutaconyl-CoA hydratase, the cardiolipin levels, and molecular analysis of the OPA3 gene, respectively, showed no abnormalities. The children presented with characteristic association of hearing loss and the neuro-radiological evidence of Leigh disease. They also had neonatal hypotonia, recurrent lactic acidemia, episodes with hypoglycemia and severe recurrent infections, feeding difficulties, failure to thrive, developmental delay, and progressive spasticity with extrapyramidal symptoms. Our patients were further biochemically characterized by a mitochondrial dysfunction and persistent urinary excretion of 3-methylglutaconic acid.
KW - 3MGA
KW - Extrapyramidal
KW - Hypoglycemia
KW - Lactic acidemia
KW - Leigh-like syndrome
KW - Mitochondrial
KW - Sensori-neural deafness
UR - http://www.scopus.com/inward/record.url?scp=33646024913&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33646024913&partnerID=8YFLogxK
U2 - 10.1016/j.ymgme.2006.01.013
DO - 10.1016/j.ymgme.2006.01.013
M3 - Article
C2 - 16527507
AN - SCOPUS:33646024913
SN - 1096-7192
VL - 88
SP - 47
EP - 52
JO - Molecular genetics and metabolism
JF - Molecular genetics and metabolism
IS - 1
ER -